Antibody Industry Trends

Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. This quarter, three novel monoclonal antibody drugs have been approved by China.

Immunoglobulin E (IgE) is a class of antibody primarily involved in allergic disease. It binds to immune cells such as mast cells and basophils and triggers inflammatory responses following allergen exposure. Anti-IgE therapies, such as omalizumab, were developed to block this interaction and reduce allergic symptoms.

Overview The concept of antibody allostery describes long-range intramolecular communication between the variable (V) and constant (C) regions.While a growing body of structural, computational, and functional studies challenges the classical model of strict domain independence,

Monoclonal antibodies have become one of the most established modalities in modern drug development, with expanding pipelines across oncology, immunology, and infectious disease. At the same time, the scale and speed of antibody discovery have changed dramatically. New discovery platforms, automatio

Fully human antibodies are monoclonal antibodies whose variable and constant regions are derived entirely from human immunoglobulin sequences. Unlike earlier therapeutic antibodies generated in murine systems and subsequently engineered through chimerization or humanization, fully human antibodies a

Introduction: Persistent Dominance of E. coli as a Protein Expression Platform Escherichia coli remains the most widely used host organism for recombinant protein production due to its rapid growth, inexpensive cultivation, and well-established genetic tools. Despite decades of use, t

Antibody therapeutics have a structural limitation: many targets such as immune checkpoints, costimulatory receptors, and broadly expressed tumor-associated antigens, cannot be engaged at pharmacologically optimal exposures without triggering dose-limiting on-target, off-tumor toxicities. In response, multiple groups are exploring antibody formats, like introducing conditionality.

Recent work in antibody-cytokine fusion proteins reflects a clear engineering objective: retain the immunostimulatory capacity of cytokines while reducing systemic toxicities associated with non-restricted receptor engagement.

Radioligand therapy (RLT), also known as radiopharmaceutical therapy, is quickly becoming a major player in the oncology therapeutics space, specifically radioantibodies.

Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends of the biopharmaceutical industry for 2026. Last year, 21 novel monoclonal antibody drugs have been approved by China, United States, Europe, and Australia.

Fusion proteins are engineered molecules combining domains from two or more distinct proteins into a single polypeptide chain to endow new or enhanced biological functions. In antibody research and drug development, fusion proteins often incorporate an immunoglobulin framework with targeting, signaling, or effector domains such as cytokines, enzymes, or synthetic peptides.

​Antibody-drug conjugates (ADCs) rely critically on the chemical linker as the molecular bridge between the antibody and the cytotoxic payload. This component governs not only stability and pharmacokinetics but also the specificity and mechanism of payload release. Recent research describes computational and chemically innovative strategies to expand the functional and pharmacological space of linkers.